Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306777 | 0.89 | PTGDR2 (0.40) | PTGDR2HDAC4CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3303664 | 0.83 | PTGDR2 (0.51) | PTGDR2ALDH1A1KDM4E | |
| SCHEMBL3303558 | 0.82 | PTGDR2 (0.50) | PTGDR2 | |
| SCHEMBL3299818 | 0.82 | PTGDR2 (0.52) | PTGDR2 | |
| SCHEMBL3299837 | 0.82 | PTGDR2 (0.53) | PTGDR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL3567663 | 0.81 | PTGDR2 (0.58) | PTGDR2AKR1B1 | |
| SCHEMBL3300935 | 0.79 | PTGDR2 (0.51) | PTGDR2LMNA | |
| SCHEMBL3570130 | 0.79 | PTGDR2 (0.56) | PTGDR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2770201 | 0.78 | PTGDR2 (0.75) | PTGDR2CYP1A2CYP3A4CYP2C9AKR1B1 | |
| SCHEMBL3577547 | 0.77 | PTGDR2 (0.65) | PTGDR2CYP2C9AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121686-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078069-A1 | INDOLIZINEACETIC ACIDS AND THEIR THERAPEUTIC USE AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093751-A1 | Indolizineacetic Acids and Their Therapeutic Use as Ligands of the CRTH2 Receptor | HRH2, HRH4, HRH1 | PTGDR2 168/4885HDAC4 2145/4885HTR1A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.